Proveedores DPC GLP-1 en 2026 — Clasificados y Revisados

La Atención Primaria Directa (DPC, por sus siglas en inglés) es un modelo de atención primaria por membresía que elimina la facturación al seguro y la reemplaza con una tarifa mensual fija. Un grupo pequeño pero creciente de prácticas DPC ha añadido medicamentos GLP-1 a la membresía a costo de mayoreo o casi mayoreo —radicalmente diferente del modelo DTC donde pagas $300-$500/mes por el medicamento sin relación de atención primaria continua. El modelo DPC integra monitoreo de laboratorio, ajustes de medicamento y manejo de efectos secundarios dentro de una relación continua con el proveedor. Las cuotas suelen ser de $50-$150/mes; el GLP-1 al por mayor cuesta $65-$300/mes según fármaco, dosis y forma. Para pacientes sin cobertura de Wegovy/Zepbound de marca, DPC puede ser el camino de menor costo total a GLP-1 más atención integral.

WeightLossRankings.org se sostiene gracias a sus lectores. Cuando compras a través de enlaces en nuestro sitio, podemos ganar una comisión de afiliados. Más información

Cómo clasificamos y qué cuenta como “legítimo”

Cada proveedor en esta clasificación se puntúa contra nuestra rúbrica de seis factores[1] publicada — valor, eficacia, experiencia del usuario, confianza y seguridad, accesibilidad y soporte.

Wegovy, Zepbound, Ozempic y Mounjaro de marca están aprobados por la FDA bajo sus propios números de NDA[4][5]. La eficacia publicada de Fase 3 para semaglutida 2.4 mg (~14.9% de pérdida de peso promedio en 68 semanas) proviene del ensayo STEP 1[6], y para tirzepatida (~20.9% en dosis de 15 mg durante 72 semanas) del SURMOUNT-1[7]; el SURMOUNT-5 comparativo publicado en 2025 comparó las dos directamente[8].

La cobertura del seguro para medicamentos contra la obesidad varía ampliamente por programa de Medicaid estatal y plan comercial[9][10]. Los GLP-1 compuestos y de marca generalmente son elegibles para FSA/HSA con receta médica según la Publicación 502 del IRS[11].

Verifica siempre los precios y la disponibilidad por estado en el sitio del proveedor antes de inscribirte.Cómo funcionan nuestras reseñas →

Selecciones rápidas: Top 1

#ProveedorPuntuación
1Primary Clinic (Direct GLP)8.0Visitar

Reseñas detalladas

1

Primary Clinic (Direct GLP)

Mejor para: Patients in the 10 covered states who want GLP-1 medications as part of a continuous Direct Primary Care relationship (including labs, routine meds, unlimited visits, and ongoing provider monitoring) rather than a transactional DTC marketplace purchase, and who calculate the $89/mo membership fee plus wholesale med cost is favorable vs $300-$500/mo all-in DTC pricing.

8.0

Primary Clinic (directglp1.com, also branded as Direct GLP) is a Direct Primary Care (DPC) telehealth membership model — fundamentally different from the DTC GLP-1 marketplace pattern that dominates the rest of the WLR directory. Members pay $89/month for unlimited primary care, direct text access to a provider, same-day virtual visits, routine labs included, and 'thousands of medications' covered. GLP-1 medications are then offered AT WHOLESALE COST to active members with no markup: compounded 503A tirzepatide ranges $110/mo at 2.5mg to $235/mo at 10mg; compounded 503A semaglutide ranges $65/mo at 0.25-0.5mg to $160/mo at 2.7mg. The DPC model means GLP-1 access is bundled with ongoing lab monitoring, medication adjustments, and side-effect management within a continuous primary care relationship. Currently serves 10 states: WA, NM, AZ, UT, FL, DC, KS, OK, VA, GA. Pharmacy partners are described as 'licensed 503A pharmacies' but not named specifically. LegitScript certification is not mentioned. Verbatim disclosure: 'These compounded products are not affiliated with or approved as generic versions of brand-name GLP-1 medications.' Live-verified 2026-05-19 via Chrome MCP (homepage is JavaScript-rendered SPA).

Desglose de puntuación

Value25%
9
Effectiveness25%
8
User Experience15%
8
Trust & Safety15%
7
Accessibility10%
6
Support10%
9

Pros

  • ✓Direct Primary Care (DPC) model integrates GLP-1 with continuous primary care — fundamentally different from DTC marketplace pattern
  • ✓GLP-1 medications at WHOLESALE COST with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
  • ✓Unlimited primary care visits + direct text access + same-day care all bundled in $89/mo membership
  • ✓Routine labs and thousands of medications included in membership (no surprise bills)
  • ✓Per-dose pricing transparency for both semaglutide and tirzepatide (all 8 dose tiers listed publicly)
  • ✓Verbatim 503A compounded-medication disclaimer published (no FDA-approval/brand-name confusion)
  • ✓Hybrid model addresses common DTC complaint of 'no continuity of care' for GLP-1 patients

Contras

  • ✗10 states only (WA/NM/AZ/UT/FL/DC/KS/OK/VA/GA) — limited national coverage vs 50-state DTC platforms
  • ✗Membership required to access wholesale GLP-1 pricing — $89/mo adds to year-1 cost (~$1,068/yr fixed)
  • ✗Specific 503A pharmacy partners NOT named
  • ✗LegitScript certification NOT mentioned on the site
  • ✗Named medical director NOT disclosed
  • ✗Corporate legal entity (LLC/Inc/PC) NOT disclosed
  • ✗Brand-name Wegovy/Ozempic/Mounjaro/Zepbound NOT offered — compounded only
  • ✗Site is fully JavaScript-rendered — limited HTML-only crawler visibility
  • ✗Refund policy NOT publicly disclosed
Desde $65/mes
Visitar Primary Clinic (Direct GLP) →

Clasificaciones relacionadas

Preguntas frecuentes

Fuentes y metodología — as of May 2026
  1. 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  5. 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  8. 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  9. 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  10. 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
  11. 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.